The Food and Drug Administration has issued Investigational Device Exemption approval to Cohera Medical's TissuGlu surgical adhesive, opening the door for a prospective, multi-center, randomized clinical trial of the product in the U.S.
According to the Pittsburgh, Pa.-based manufacturer, the absorbable internal surgical adhesive, intended for the sealing of tissue in large-flap surgeries such as abdominoplasty, can prevent fluid accumulation in post-op wounds. This would reduce the need for surgical drains and possibly speed patients' recoveries.
At present, says Cohera Medical, no synthetic adhesive product is available or in clinical trials for use in large-flap tissue surgeries. TissuGlu received the European Union's safety and effectiveness approval last year, and is scheduled to begin U.S. testing in the first quarter of this year.
No comments:
Post a Comment